IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jacob Bar-Tana

Serial No.: Not Yet Known

Filed : Herewith

For : METHODS FOR THE TREATMENT OF SYNDROME X USING

XENOBIOTIC FATTY ACID COMPOUNDS

1185 Avenue of the Americas New York, New York 10036 December 11, 2003

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450 Mail Stop: Patent Applications

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (Exhibit A).

- 1. U.S. Patent No. 4,634,795, issued on January 6, 1987 to Bar-Tana;
- 2. U.S. Patent No. 4,689,344, issued on August 25, 1987 to Bar-Tana;
- 3. U.S. Patent No. 4,711,896, issued on December 8, 1987 to Bar-Tana et al.;
- 4. U.S. Patent No. 4,954,487, issued on September 4, 1990 to

Filed : Herewith

Page 2

Cooper etal.;

- 5. U.S. Patent No. 5,502,226, issued on March 26, 1996 to .Cho et al.;
- 6. U.S. Patent No. 5,502,077, issued on March 26, 1996 to Breivik et al.;
- 7. U.S. Patent No. 5,641,810, issued onJune 24, 1997 to Pill et al.;
- 8. U.S. Patent No. 6,303,653, issued on October 16, 2001 to Bar-Tana, attached hereto as **Exhibit 1**;
- 9. International PCT Application No. WO 98/30530;
- 10. International PCT Application No. WO 98/36745;
- 11. Israel Patent No. 119971;
- 12. Israel Patent No. 121165;
- 13. European Patent No. 0661049;
- 14. European Patent No. 0081930;
- 15. Bar-Tana et al., "Inhibition of lipid synthesis by β,β' tetramethyl-substituted C14-C22 α,ω dicarboxilic acids in the rat in vivo", J. Biol. Chem., 260:8404-8410 (1985);
- 16. Bar-Tana et al., "Hypolipidemic effect of β, β' -methyl-

Filed : Herewith

Page 3

substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats", J. Lipid Res., 29:431-441 (1988), attached hereto as **Exhibit 2**;

- 17. Bar-Tana et al., "Hypolipidemic effect of β , β' -methyl-substituted hexadecanedioic acid in normal and nephrotic rats", J. Lipid Res., 29:4431-441 (1998);
- 18. Bar-Tana et al., "Long chain dicarboxylic acids: Hypolipidemic, antiobesity and antidiabetic activity", New Antibiotic Drugs, (Eds. Bailey, C.J., Flatt P.R.). Smity-Torton and Comp. (1990);
- 19. Bar-Tana et al., "Synthesis, hypolipidemic and antidiabetogenic activities of β,β' tetra-substituted, long chain dioic acids", J. Med. Chem., 32:2072-2084 (1989);
- 20. Cave, W.T., "Dietary n-3 (omega-3) polyunsaturated fatty acid effects on animal tumorigenesis", FASEB J., 5:52160-2166 (1991);
- 21. Chin, J.P.F., Prost. Leuk. Essent. Fatty Acids, 50:211-222 (1994);
- 22. De-Fronzo et al., "Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease", Diabetes Care, 3:173-194 (1991);
- 23. Frenkel et al., "The effect of β,β' -methyl-substituted

Filed : Herewith

Page 4

hexadecanedioic acid on VLDL metabolism in rats: role of apolipoprotein C-IIL", Biochem. J., 298:409-414 (1994);

- 24. Frenkel et al., "The hypochylomicronemic effect of β , β' methyl-substituted hexadecanedioic acid is mediated by a decrease in apolipoprotein C-IIL", J. Biol. Chem., 263:8491-8497 (1988);
- 25. Grundy, S.M. & Denke, M.A., "Dietary influences on serum lipids and lipoproteins", J. Lipid Res., 31:1149-1172 (1990);
- 26. Hall et al., "The role of coenzyme A in the biotransformation of 2-arylpropionic acids", Chem. Biol. Interact., 90(3):235-252 (1994);
- 27. Hermesh et al., "Mitochondria uncoupling by a long chain fatty acyl analog", J. Biol. Chem., 273:3937-3942 (1997);
- 28. Hertz et al., "Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-IIL", J. Biol. Chem., 270:13470-13475 (1995);
- 29. Hultin, M.B., "Fibrinogen and Factor VII as risk factors in vascular disease", Prog. Hemost. Thromb., 10:215-241 (1991), attached hereto as Exhibit 3;
- 30. Jeppesen et al., "Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease", Arch. Intern. Med., 161:361-366 (2001);

Filed : Herewith

Page 5

- 31. Kahn-Rose et al., "Inhibition of lipid synthesis by β,β' tetramethyl-substituted C14-C22 α,ω dicarboxilic acids in cultured rat hepatocytes", J. Biol. Chem., 260:8411-8415 (1985);
- 32. Kalderon et al., "Tissue selective modulation of redox and phosphate potentials by β , β' -methyl-substituted hexadecanedioic acid", Endocrinology, 131:162-165 (1992);
- 33. Leff, T., Reue, K., Melian, A., Culver, H. & Breslow J.L., "A regulatory element in the ApoCIII promoter that directs hepatic specific transcription binds to proteins in expressing and nonexpressing cell types", J. Biol. Chem., 264:16132-16137 (1989);
- 34. Limatta et al., "Dietary Polyunsaturated Fatty Acids Interfere with the Insulin/Glucose Activation of I-type Pyruvate Kinase Gene Transcription", Molecular Endocrinology, 8:1147-1153 (1994);
- 35. Mayorek et al., Hypocholesterolemic effect of β , β' -methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo", 289:911-917 (1993);
- 36. Mayorek et al., "Sensitization to insulin induced by β , β' -methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo", Diabetes, (1997);
- 37. Morris, M.C., Saks, F. & Rosner, B. Circulation 88, 523-533 (1993);

Filed : Herewith

Page 6

- 38. Neupert et al., "Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases", BR. J. Pharmacol., 122(3):487-492 (1997);
- 39. Russel et al., "The hypolipidemic effect of β , β' tetramethylhexadecanedioic acid (MEDICA 16) in hyperlipidemic JCR:LA-corpulent rats", Arteriosclerosis and Thrombosis, 11:602-609 (1991);
- 40. Russell et al., "Inhibition of arherosclerosis and myocardial lesions in the JCR:LA-cp rat by β , β' -tetramethyl hexadecanedioic acid", Arterioscler. Thromb. Vasc. Biol., 15:918-923 (1991);
- 41. Sladek, F.M., "Liver Gene Expression" (eds. Tronche, F. & Yaniv, M.) pp. 207-230, R.G. Landes Co., Austin, TX (1994);
- 42. Sladek, F.M., Zhong, W.M., Lai, E. Darnell, J.E., Jr. Gene Dev., 4:233-2365 (1990);
- 43. Storlien, L.H. et al., "Fish oil prevents insulin resistance induced by high-fat feeding in rats", Science, 237:885-888 (1987);
- 44. The Metabolic and Inherited Bases of Inherited Disease (eds., Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D.) Vol. II, Part 8, 1995 (McGraw-Hill, Inc.);
- 45. Tracy et al., "Metabolic inversion of (R)-ibuprofen-Coenzyme A", Drug Metabol. Dispos., 21(1):114-120 (1993);

Filed : Herewith

Page 7

- 46. Tzur et al., "Adipose reduction by β , β' -tetramyethyl-substituted hexadecanedioic acid (MEDICA 16)", Int. J. Obesity, 13:313-326 (1989);
- 47. Tzur et al., "The hypolipidemic antiobesity and hypoglycemic-hypoinsulinemic effects of β , β' -methylsubstituted hexadecanedioic acid in sand rats", Diabetes, 37:1618-1624 (1988);
- 48. Unger, R.H., "Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications", Diabetes 44, 863-870 (1995); and
- 49. Yamagata, K. et al., "Mutations in hepatic nuclear factor alpha gene in maturity onset diabetes of the young (MODY 1)", Nature, 384:458-460 (1996).

The subject application is a continuation of and claims the benefit under 35 U.S.C. §120 of U.S. Serial No. 09/915,412, filed July 25, 2001, which is a divisional of U.S. Serial No. 09/104,880, filed June 25, 1998, now U.S. patent No. 6,303,653, issued on October 16, 2001, claiming priority of Israeli Application No. 121165, filed June 26, 1997.

Above-listed references 1-3, 7, 9, 11, 12, 15, 17-19, 22-24, 27, 28, 31, 32, 34-36, 39-40 and 46-47 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed in connection with U.S. Serial No. 09/104,880, filed June 25, 1998. Above-listed references 4 and 5 were cited by the United States Patent and Trademark Office in an Office Action dated September 16, 2002 in connection with 09/915,412, issued July 25, 2001. Above-

Filed : Herewith

Page 8

listed references 6, 10, 13, 14, 26, 38 and 45 were submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on November 12, 2002 in connection with U.S. Serial No. 09/915,412, filed July 25, 2001. Accordingly, under 37 C.F.R. \$1.98(d) copies of these references are not required to be provided to the United States Patent and Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier effective filing date under 35 U.S.C. §120. Copies of above-cited references 20, 21, 25, 29, 33, 37, 41-44 and 48-49 have not yet been submitted or considered by the U.S Patent Office. Applicant will submit copies of each of these references in a Supplemental Information Disclosure Statement as soon as such copies are obtained. Copies of above-cited references 8, 16 and 30 are submitted herewith, as Exhibit 1, 2 and 3, respectively.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Filed

: Herewith

Page 9

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is deemed necessary

in connection with the filing of this Information Disclosure Statement. However, if any fee is required authorization is hereby given to charge the amount of any such fee to Deposit

Account No. 03-3125.

Respectfully submitted,

John P. White

Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas

New York, NY 10036

(212) 278-0400

Sheet 1 of 8

Form	PTO-	1449				Commerce rk Office	Atty. Docker 1567/70937- Applicant(s) Jacob Bar-T	ZA	Serial No. Not Yet K	
	INFO		ON DISCL veral sheet			ION	Filing Date Herewith		Group Ar	t Unit
				U.S.	PATENT	T DOCUMI	ENTS .			
Examin Initials			nt Number	Date	N	Name	Class	Subclas	1 0	Date propriate
			3 4 7 9 5		ļ					
			8 9 3 4 4 1 1 8 9 6		ļ					
										·
ļ	_		5 4 4 8							
			0 2 2 2 6							
				7						
			4 1 8 1 (
		6 3	0 3 6 5 3	3						
				FOREI	GN PATE	ENT DOCU	MENTS	-		
									Tran	slation
		Docu	ment Numbe	er	Date	Name	Class	Subclas	Yes	No
	WO	98 3	0 5 3 0		,					
	WO	98 3	6 7 4 5							
	IS	1	1 9 9 7							
	IS	1	2 1 1 6							
	EPO EPO	0 6	6 1 0 4 8 1 9 3	9	***************************************				•	ļ
	EPO	10 10	0 1 9 3		· · · · · · · · · · · · · · · · · · ·			 		
	0'	THER D	OCUMEN	ITS (Inc	luding A	uthor Title	e, Date, Pert	inent Pag	es Etc.)	<u></u>
	\Box	Bar-T					of lipid	_		β,β'
		tetra	methyl-si	ubstit Biol. (uted C1 Chem.,	4-C22 α,ω 260:8404-	dicarbox 8410 (198	ilic ac 5);	ids in t	the rat
		Bar-T	ana et a	l., "H	ypolipi	demic eff	ect of β,	β'-meth	yl-subst	tituted
			ecanedio. pid Res.				n normal	and ne	phrotic.	rats",
		Bar-T	ana et a	l., "H	ypolipi	demic eff	ect of β,			
						normal a	nd nephro	otic ra	ts", J.	Lipid
_			29:4431-			ain dica	rboxylic	acids	Hypolip	idemic.
		antio	besity a	ind an	tidiabe	tic acti	vity", N	ew Anti	.biotic	Drugs,
		(Eds.	Bailey,	C.J.,	Flatt	P.R.). Sm	ity-Torto	n and C	omp. (19	90);
		Bar-T	ana et a ities of	al., "	Synthes tetra-s	is, hypo.	lipidemic d, long c	and an	tidiabet	cogenic
			Chem., 32				.a, rong C	TIGTII UT	ore acte	, U.
EXAM	INER	•				NSIDERED		6		
							onformance wi m with next co			

Form PT	O-1	449							nent of Commerce Trademark Office	Atty. Docket 1567/70937-2	ZA		al No. Yet Kn	iown	
										Applicant(s) Jacob Bar-T					
IN]	FOI							OSURE if nece	E CITATION ssary)	Filing Date Herewith		Gro	up Art	Unit	
					-			U.S.	PATENT DOCUME	ENTS		<u> </u>			
Examiner Initials		Doc	umo	ent I	Nun	nbe	r	Date	Name	Class	Subclas		Translation Yes No S, Etc.) d fatty ac -2166 (1991 50:211-2 eted syndro ipidemia a re, 3:173-1 l-substitut s: role		
			_	-			_								
			+									-			
			-	+		Н	_								
			-	+		Н	+	· · ·				.			
		\vdash	+	+			-						-		
		-	-	+		\dashv	-								
			-	+		\dashv	\dashv								
		<u></u>	<u> </u>			Ш		OPFIC	SN PATENT DOCU	MENTS					
								OKEIC	INTATENT BOCO	MIENIS	1	Τ,	ar	1 . 4	
Examiner		. Doc	ume	ent I	Vun	nbe	r	Date	Name	Class	Subclas				
Initials		. Document Number			_					-	res	NO			
			+			-	-						-		
			╁			-	\dashv				l. 				
			T				\top								
			L				\perp								
			\perp			-	\dashv			<u> </u>			····		
	\mathbf{O}	HE	S L	\mathbf{D}	<u>ן</u>	MF	EN'	TS (Inc	luding Author, Title	Date Perti	inent Pag	es E	tc)		
								•	ry n-3 (omega-3		_	•	٠.	acid	
		eff	ec	ts	on	ı a	ni	mal tı	umorigenesis",	FASEB J.,	5:5216	0-21	.66 (1991);	
		Chi (19			J.P	. F	.,	Pros	st. Leuk. Esse	nt. Fatt	y Acid	s,	50:2	11-222	
						e1	t	al.,	"Insulin resist	ance: a r	nultifac	cete	d sy	ndrome	
		res	ро	nsi	ibl	.e	fo	or NII	DDM, obesity, h	ypertensi	on, dys	slip	idemi	a and	
		ath (19			cle	ero	tí	c card	diovascular dise	ase", Dia	petes C	are,	3:1	/3-194	
		Fre				et		al.,	"The effect	of β,	β'-meth	yl-s	subst	ituted	
									id on VLDL me			ats:		le of	
		Fre	nk	po <u>r</u>	et	t .	:⊥n al	., "Th	L", Biochem. J., ne hypochylomicr	conemic ef	ffect o	14); f В.	β'-m	ethvl-	
		sub	st	itι	ıte	ed	he	exadec	anedioic acid	is mediat	ed by	a d	ecrea	se in	
		apo	li	pop	oro	te	ein	C-III	L", J. Biol. Che	m., 263:8	491-849	7 (1	.988)	;	
EXAMINE	R								DATE CONSIDERED				•		

Sheet 3 of 8

Form PTO	9					nent of Commerce Trademark Office	Atty. Docke 1567/70937-		Serial No. Not Yet K	nown			
								Applicant(s Jacob Bar-					
INF						LOSURE	CITATION ssary)	Filing Date Herewith	******** *	Group Art Unit			
						U.S.	PATENT DOCUME	LENTS			<u> </u>		
Examiner Initials	D	ocui	nent	Nu	mber	Date	Name	Class	Subclas		Date propriate		
	-		\perp		-	-							
				-	++								
					++								
	-			+	-						·		
			*	+									
						FOREIC	ON PATENT DOCU	MENTS	1				
											slation		
Examiner Initials Examiner Initials Examiner Initials	D	ocur	nent	Nui	mber	Date	Name	Class	Subclas	s Yes	No		
				$\perp \mid$									
	+	\dashv		H									
		\dashv	-	$\forall \exists$							-		
							luding Author, Title						
							e, M.A., ``Dieta J. Lipid Res.,				lipids		
							cole of coenzyme				ion of		
	I .				pion	ic aci	lds'', Chem. B	iol. Int	eract.,	90(3):2	235-252		
			4); esh		t a	1., ''M	Mitochondria unc	oupling h	oy a lor	ng chair	fattv		
							ol. Chem., 273:		-	_	7		
	H	ert	z e	et	al.	, ``Mo	de of action o	f peroxi	some pro	oliferat	ors as		
	h	уро	lip	ide	emic	drugs	: suppression	of apoli	_				
EVAMINED		iol	. c	her	m.,	270:134	170-13475 (1995 DATE CONSIDERED);					
EARWIINER							DATE CONSIDERED						
*EXAMINER							ther or not citation is in c						

Sheet 4 of 8

Form PTO							nent of Commerce rademark Office	Atty. Docket 1567/70937- Applicant(s) Jacob Bar-T	ZA	Translation Yes No t Pages, Etc.) risk factors in 5-241 (1991); igh high-density heart disease'',					
INFO				_				SURE f neces	CITATION ssary)	Filing Date Herewith		Gro	oup Art	Unit	
					-			U.S. 1	PATENT DOCUMI	ENTS		1			
Examiner Initials	I	Docı	ıme	ent l	Nun	nbei	r	Date	Name	Class	Subclas	ss			
			-								 				
	+-	-				Н						-			
	\top		 	П		\Box									
							FC	DREIG	N PATENT DOCU	MENTS					
Examiner		Dogument Numb						Date	Name	Class	Subalas				
Initials	Document Number							Date	Name	Class	Subcias	Group Art Unit ass Filing Date If Appropria Translatio Yes N ges, Etc.) isk factors (1991); high-densi eart disease hesis by lic acids 1-8415 (1985 of redox a	No		
	\dashv	\vdash	\Box												
	_	ļ	\vdash		\vdash	- -			•						
		-	H			\dashv	+					-			
	_		\Box				+				<u> </u>				
(OTE	E	R D	00				•	luding Author, Title		_				
			ti												
			pe:				eas	a1	Prog. Hemost. T	nromb., I	0:215-24	41 (1991,	engit	
								olest	erol and risk	of ische	emic he	art	dise	ease''	
		-	_				. M	ſed.,	161:361-366 (20	01);			•		
	I	(ah	n-1	Ros	se	е	t	al.,	"Inhibition	of lipid	_				
									ted C14-C22						
	I	oho	spl	hat	te	po	ote:	ntial	s by , '-meth	yl-substi					
		aci	d''	<u>, , </u>	En	do	cri		y, 131:162-165	(1992);	757				
EXAMINER									DATE CONSIDERED			•			

Sheet 5 of 8

Form PTC						•	nent of Commerce Crademark Office	Atty. Docket 1567/70937-			al No. Yet Kı	10Wn			
****		~ ~ .	~~~			~~.	~-	~ ~ ~ TIP Y		Applicant(s) Jacob Bar-T					
INF								OSURE s if nece	E CITATION ssary)	Filing Date Herewith		Gro	up Art	Unit	
								U.S.	PATENT DOCUMI	ENTS		1			
Examiner Initials Examiner Initials		Doc	:um	ent	Nui	mbe	er	Date	Name	Class	Subclas		Filing If App	Date ropriate	
		+	+	+	\vdash	\dashv	H					-			
	\dashv	+	+	+	+	H	\vdash				<u> </u>		-		
	\exists	+	+	+	+	+-									
		\top	\dagger	\dagger		\prod					-				
				L									•		
			L												
· · · · · · · · · · · · · · · · · · ·							H	OREIC	GN PATENT DOCU	IMENTS	ı	- 1			
Examiner		Document Number					er	Date	Name	Class	Subclas		Translation Yes		
		Document Number							418		0	<u> </u>	Yes	No	
			+	\vdash	\dashv	\dashv	$\vdash \vdash$								
	-	+	+	-	\forall										
	\Box		工		\Box										
		+	+	\vdash	igert	\dashv	$\vdash \vdash$				•	_			
	-+	+	+	\vdash	H	\dashv	\vdash				<u> </u>				
	OT	HE	RI	000	CU	MJ	EN	TS (Inc	luding Author, Title	e, Date, Pert	inent Pag	es, E	tc.)	l	
		spe nor (19	gul eci nex 989	ate fi pr	ory c ess	y e tr sin	el car ng	ement nscript cell	, Melian, A., C in the ApoCIII tion binds to types'', J. E	promoter proteins	that d in e	irec expre	ts hessin	epatic g and -16137	
		wit Ger (19	th ne 994	tł ,	ne Tra	Ir ans	nsı	ulin/G ciptior	Dietary Polyunsa lucose Activati 1'', Molecular	on of I- Endocri	type Py inology,	yruv 8	ate 3:114	Kinase 7-1153	
		suk in	ost vi	it vo	ute	ed 2	he 89	exadeca 9:911-9	Hypocholesterole anedioic acid (N 217 (1993);	MEDICA 16)	in obe	se Z	Zucke		
		met	hy	1-	suk	bst	it	tuted	Sensitization hexadecanedioic	acid (, - obese	
EXAMINE	R								DATE CONSIDERED				,		
*EXAMINE	<u> </u>		1 : 6 -									•			

Sheet 6 of 8

Form PTO	-14	149						ment of Commerce Trademark Office	Atty. Docket 1567/70937-	t No. ZA	Serial No Not Yet I	
LNIE	AD.	ълга	TT	ONI	DI	100	r Octub	E CITATION	Applicant(s) Jacob Bar-T			į
INFO							ets if nec	E CITATION essary)	Filing Date Herewith		Group A	rt Unit
							U.S.	PATENT DOCUME	ENTS		l	
Examiner Initials		Doc	ume	nt l	Nun	nbei	Date	Name	Class	Subclas		g Date propriate
	1	_		Ш								
-	4	<u> </u>			_							
	_	-		Н								
			ļ				1.					
						\perp						
			ļ ·	Ш		\perp						
			<u> </u>									
<u>.</u>												
							FOREI	GN PATENT DOCU	MENTS		•	
Examiner Initials		Doci	ıme	nt N	Nun	nber	Date	Name	Class	Subclas		nslation No
Initials	\dashv	1			T							
	_	_	\perp	_	_							
	-		\sqcup	_	\perp	_						
	-		\vdash	-	+	-					•	
	\dashv	_	H		+	\dashv					<u> </u>	
. (TC	HEI	R D	od	CUN	ME	NTS (In	cluding Author, Title	, Date, Pert	inent Pag	es, Etc.)	
		Mor (19	ri	s,			•			culation		523-533
	- 1		_					''Effects of it	_			
								sters on human				eroxide
	_	syn Rus				. , t	al.,	Pharmacol., 122	(3):487-49 pidemic			
		tet	rai	met	hy	lhe	exadeca	nedioic acid (MEDICA 1	5) in	hyperli	pidemic
		JCR	: L	A - c	or	pu:		ts", Arterioscl				
		609						T-1212	-1			
								Inhibition of a LA-cp rat by ,				
								r. Thromb. Vasc.				HEULUIC
EXAMINER								DATE CONSIDERED	•			
								ether or not citation is in co				

Form PT	O-1	449							nent of Commerce Trademark Office	Atty. Docket 1567/70937-2		Serial No. Not Yet Known									
										Applicant(s) Jacob Bar-T			· · · · · ·								
IN	FOI							OSURE s if nece	C CITATION ssary)	Filing Date Herewith		Gı	roup Art	oup Art Unit							
								U.S.	PATENT DOCUME	ENTS		L	-								
Examiner Initials		Doc	u m	ent	Nu	mbe	er	Date	Name	Class	Subclas	ss	Filing If App	Date ropriate							
			-	+		\vdash	\vdash														
				\dagger																	
		_	-	-		-															
			+-	-	-	-								······································							
		+	-	+																	
]	FOREIC	ON PATENT DOCU	MENTS	1										
Examiner		Document Number Date							Document Number Date						Date	Name	Class	Subclas	Subclass		lation No
Initials													Yes	110							
		_	+	<u> </u>																	
									-												
		\perp	+	H	\vdash						t										
	OI	HE	R D	00	CU	M	EN	TS (Inc	luding Author, Title	, Date, Pert	inent Pag	es,	Etc.)								
									ver Gene Expre 230, R.G. Landes					F. &							
		Sla	de	k,	F	. M	٠,	Zhong	, W.M., Lai, E.					Dev.,							
								990); [. et	al., ''Fish oi	l prevent	s insu	lin	resi	stance							
			luc	ed					at feeding in												
		The	1	Met					Inherited Bases												
									det, A.L., Sly, l, Inc.);	W.S., Val	le, D.)	·Vo	ol. II	, Part							
EXAMINE	R	<u> </u>				<u>-</u>			DATE CONSIDERED												
									ther or not citation is in c												
																					
l													•								

Sheet 8 of 8

Form PTO						ment of Commerce Frademark Office	Atty. Docket 1567/70937-	ZA	Serial No. Not Yet K	nown		
									Applicant(s) Jacob Bar-T			
INF							LOSURI	E CITATION essary)	Filing Date Group Art U Herewith			
							U.S.	PATENT DOCUMI	ENTS		<u></u>	
Examiner Initials		Doc	ume	ent l	Nun	nber	Date	Name	Class	Subclas	1 9	Date propriate
		-	-	+			-		<u></u>			
		_	╁╌	+				·				-
	+		 									
	1		†								•	·
							FOREI	GN PATENT DOCU	JMENTS			
Examiner		Doc	ume	ent l	Num	nber	Date	Name	Class	Subclas		slation
Initials		1	1			1					Yes	No
						_						
	_		-			-						
	-	+	\vdash		\dashv	-						
	OT	HEI	R D	000	CUI	ME	VTS (Inc	cluding Author, Title	e, Date, Pert	inent Pag	ges, Etc.)	
		Tra						etabolic invers			rofen-C	oenzyme
								Dispos., 21(1):1 ose reduction by			yl-subst	tituted
		hex (19	ad 89	eca);	ane	dio	ic aci	.d (MEDICA 16)''	, Int. J	. Obesi	ty, 13:	313-326
								hypolipidemic effects of		_	hypogly nyl-subst	•
			ad	eca				id in sand r				
		Ung	er	,				potoxicity in				
							DDM. G 1995);	enetic and climand	nical imp	olicatio	ns'', D	iabetes
		Yan	ag	ata	a,	K.	et al.	., ''Mutations i				
							ity on 1996).	set diabetes of	the young	g (MODY	1)'', 1	Nature,
EXAMINE	R							DATE CONSIDERED				
											•	